Qiao Li

20PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 07, 2026
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

|Jun 23, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort Study.

|May 11, 2026
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study.

|Jan 05, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study.

Xuenan Peng, Ruixia Song, Ying Fan

|Nov 12, 2025
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens.

Jiaxuan Liu, Hongnan Mo, Qiao Li

|Sep 13, 2024
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.

Qi Zhao, Mingxia Jiang, Jiaxuan Liu

Pageof 4

Frequent Collaborators

7 joint publications

Fei Ma

6 joint publications

Binghe Xu

5 joint publications

Bo Lan

4 joint publications

Binghe Xu